Manufacturing license has been granted by The Gujarat Food and Drug Control Administration (FDCA) to Prague-headquartered Zentiva Pvt Ltd which manufactures APIs and formulations by investing of Rs. 250 crore with foreign direct investment (FDI) as approved by the Centre.
The welcome move has come as the state has witnessed an increase in the interest from both foreign and domestic players in commissioning plants of APIs, formulations and medical devices since July 2015 after the introduction of goods and services tax (GST).
Dr. HG Koshia, Gujarat Food and Drug Control (FDCA) Commissioner informed that the, “Gujarat FDCA gave manufacturing approval within three days of the application despite the lockdown period. The company will make an investment of Rs. 250 crore initially at the Ankleshwar facility and plans to invest another Rs. 50 crore by the end of the year to further its expansion plans. To give the much required boost to the domestic pharmaceutical industry, Gujarat FDCA has also approved layout designs for 252 companies till date.”
Based on the layout design approvals of plants, these are the major companies to start operations Exotic Pharma, Godhara, Aashka Formulation, Gandhinagar, Akshar Air Gases, Surat, Swan Medicot Morbid, Fishfa Biogenics, Rajkot, Chevron Pharma, Bharuch, Alidac Pharmaceuticals, Ahmedabad Rural, Madilyn Healthcare, Ahmedabad Rural, M J Healthcare, Mehsana, Labron Healthcare, Mehsana, Trio Lifescience, Ahmedabad city, Punishka Healthcare, Edkem Pharmaceuticals, Avantika Medex, Derek Healthcare, Dewcare Concept, Afeel Life Care, Rajkot and Moksh Pharmaceuticals, Vadodara.
